The company has not filed an annual or quarterly report since its Q2 FY2023 10-Q, filed Feb 9, 2023. Its latest SEC filing is a SC 13G/A from Feb 13, 2024.
10-Q for Q2 FY2023, filed Feb 9, 2023
The sections below describe the company as of the FY2022 annual report.
Sells catheter-based devices for preparing leg arteries for peripheral artery disease treatment and treating calcified coronary arteries, primarily to hospitals and office-based labs.
10-K for FY2022, filed Aug 18, 2022Our peripheral artery disease (“PAD”) products are catheter-based platforms capable of treating a broad range of plaque types in leg…View ↗
Our coronary artery disease (“CAD”) product, the Diamondback 360 Coronary OAS (“Coronary OAS”), is a catheter-based platform designed to…View ↗
We market and sell the majority of our products through a direct sales force in the United States, with direct shipments to hospitals or…View ↗
Hospitals, clinics and international distributors buy single-use peripheral and coronary products; most sales are completed when products ship or arrive at the customer site. In Japan, Medikit pays in advance for orders, with sales completed when it accepts the products.
10-K for FY2022, filed Aug 18, 2022The Company sells its peripheral and coronary products to customers through a direct sales force in the United States and through…View ↗
The majority of the Company’s revenues are from customer arrangements containing a single performance obligation to transfer control of…View ↗
The Company has an exclusive distribution agreement with Medikit to sell the Company’s coronary and peripheral OAS in Japan. To secure…View ↗
10-K for FY2022, filed Aug 18, 2022
FY2022 revenue by product or service ↗$236.2M
10-K for FY2022, filed Aug 19, 2022
$236.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Peripheral
Sold outright
10-K for FY2022, filed Aug 18, 2022 |
66%
FY2019: 72%
|
Peripheral, FY2022
$156M Sources
|
Sold outright |
|
Coronary
Sold outright
10-K for FY2022, filed Aug 18, 2022 |
34%
FY2019: 28%
|
Coronary, FY2022
$80.2M Sources
|
Sold outright |
In the United States, hospitals and office-based labs receive products shipped directly from the company. Outside the United States, sales go through distributors and sales agents, including Medikit in Japan.
10-K for FY2022, filed Aug 18, 2022We market and sell the majority of our products through a direct sales force in the United States, with direct shipments to hospitals or…View ↗
Sales of our products outside of the United States are currently made through a network of distributors and sales agents.View ↗
We serve a growing patient population globally through an expanding distribution and sales network. Sales of our approved products in Japan…View ↗
No. It lost $36.9M in FY2022.
10-K for FY2022, filed Aug 19, 2022
−$35.8MView ↗
10-K for FY2022, filed Aug 19, 2022
−$36.9MView ↗
10-K for FY2022, filed Aug 19, 2022
−$28.5MView ↗
10-Q for Q2 FY2023, filed Feb 10, 2023
−$7.9MView ↗
10-Q for Q2 FY2023, filed Feb 9, 2023
Open tableView ↗
8-K, filed Apr 27, 2023
On April 27, 2023 (the “Closing Date”), Cardiovascular Systems, Inc., a Delaware corporation (“CSI”), was acquired by Abbott Laboratories…View ↗
8-K, filed Apr 13, 2023
The consummation of the Merger is conditioned upon, among other things, the expiration or termination of the applicable waiting period (or…View ↗
8-K, filed Feb 9, 2023
On February 8, 2023, Cardiovascular Systems, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger…View ↗
Grew. Revenue grew 9% in 4 years, from $217M in FY2018 to $236.2M in FY2022, about 2% a year.
Added embolic protection
The latest report adds WIRION, an embolic protection system for peripheral interventions that can be used with multiple atherectomy devices.
International sales channels
International sales in the rest of the world moved from an exclusive distributor to a network of distributors and sales agents; Japan continued through Medikit.
10-K for FY2019, filed Aug 23, 2019 10-K for FY2022, filed Aug 18, 2022In October 2014, we received CE Mark for our Stealth 360 Peripheral OAS, and in fiscal 2019, we commenced sales of this product in certain…View ↗
We serve a growing patient population globally through an expanding distribution and sales network. Sales of our approved products in Japan…View ↗
Competes with Abbott Laboratories, Boston Scientific, Medtronic, Cook Medical, Johnson & Johnson, Becton Dickinson, Terumo, Asahi, Teleflex, Cordis, Philips/Spectranetics, Ra Medical, Angiodynamics, Shockwave, Avinger, and Cardio Flow
10-K for FY2022, filed Aug 18, 2022The medical device industry is highly competitive, subject to rapid change and significantly affected by new product introductions and…View ↗
Loading...
